Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-06
2007-02-06
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S373000, C514S443000, C546S198000, C548S207000, C549S049000, C549S053000, C549S058000
Reexamination Certificate
active
11178164
ABSTRACT:
The present invention relates to heteroaromate OSC inhibitors. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.
REFERENCES:
patent: 4410539 (1983-10-01), Cross et al.
patent: 5994371 (1999-11-01), Black et al.
patent: 39 05 364 (1990-08-01), None
patent: 778 271 (1997-06-01), None
patent: WO 98/21188 (1998-05-01), None
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
Gotto et al., Circulation 81, pp. 1721-1733 (1990).
Stein et al., Nutr. Metab. Cardiovasc. Dis. 2, pp. 113-156 (1992).
Illingworth, Med. Clin. North Am. 84, pp. 23-42 (2000).
Ross et al., Arch. Intern. Med. 159, pp. 1793-1802 (1999).
Ellen et al., J. Cardiol. 81, pp. 60B-65B (1998).
Shepherd, Eur. Heart J. pp. 5-13 (1995).
Davignon et al., Can. J. Cardiol. 8, pp. 843-864 (1992).
Pedersen et al., Drug Safety 14, pp. 11-24 (1996).
Morand et al., J. Lipid Research 38, pp. 373-390 (1997).
Mark et al., J. Lipid Research 37, pp. 148-158 (1996).
Peffley et al., Biochem. Pharmacol 56, pp. 439-449 (1998).
Nelson et al., J. Biol. Chem. 256, pp. 1067-1068 (1981).
Spencer et al., J. Biol. Chem. 260, pp. 13391-13394 (1985).
Panini et al., J. Lipid Research 27, pp. 1190-1204 (1986).
Ness et al., Arch. Biochem. Biophys. 308, pp. 420-425 (1994).
Janowski et al., Proc. Natl. Acad. Sci. USA 96, pp. 266-271 (1999).
Venkateswaran et al., J. Biol. Chem. 275, pp. 14700-14707 (2000).
Costet et al., J. Biol. Chem. 275, pp. 28240-28245 (2000).
Ordovas et al., Nutr. Rev. 58, pp. 76-79 (2000).
Schmitz et al.. Front. Biosci 6, D505-D514 (2001).
Tobin et al., Mol. Endocrinol. 14, pp. 741-752 (2000).
Marshall et al., J. Org. Chem. 61(17), pp. 5729-5735 (1996).
Baker et al., J. Chem. Soc. Perkin. Trans. l, pp. 1415-1421 (1990).
Belostotskii et al., Tetrahedron Letters 35(28), pp. 5075-5076 (1994).
Wolfe et al., J. Org. Chem., 65(4), pp. 1158-1174 (2000).
Palucki et al., J. Am. Chem. Soci., 119(14), pp. 3395-3396 (1997).
Denton et al., Synlett, No. 1, pp. 55-56 (1999).
Chaplinski et al., Angew. Chem. Int. Ed. Engl., 35, pp. 413-414 (1996).
Mattson et al., J. Org. Chem., 55, pp. 2552-2554 (1990).
Stara et al., Collect. Czech. Chem. Commun. 64(4), pp. 649-672 (1999).
P.E. Cross, et al,Journal of Medicinal Chemistry, 29(9), pp. 1637-1643 (1986).
Ackermann Jean
Aebi Johannes
Dehmlow Henrietta
Maerki Hans-Peter
Morand Olivier
Anderson Rebecca
Hoffmann-La Roche Inc.
Johnston George W.
Rocha-Tramaloni Patricia S.
LandOfFree
Heteroaromate OSC inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaromate OSC inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaromate OSC inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3886014